Incidence and risk quantification of Herpes Zoster (shingles) infections in people iwth autoimmune diseasesor other comorbidities in Ontario

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2022-149/ 2024 0970 365 000

Research Question/Objectives: The objective of this study is to better understand the incidence and risk factors of developing HZ and PHN in the adult population (18+) in Ontario.

Objectives:

Primary objectives:
1. Estimate the annual incidence of HZ in the general adult (18+) Ontario population
2. Estimate the annual incidence of HZ among adults (18+) with AID or comorbidities in Ontario. The following are the AIDs and comorbidities of interest:

• AIDs

o Rheumatoid arthritis (RA)
o Systemic lupus erythematosus (SLE)
o Inflammatory bowel disease (IBD)
o Psoriatic arthritis (PsA)
o Multiple sclerosis (MS)

•  Comorbidities

o Diabetes
o Asthma
o Chronic obstructive pulmonary disease (COPD)
o Chronic kidney disease (CKD)
o Cardiovascular disease (CVD)
o Cerebrovascular disease

Secondary objectives:

1. Estimate the proportion of HZ patients in the general adult (18+) Ontario population who develop PHN
2. Estimate the proportion of HZ patients among adults with AID in Ontario who develop PHN
3. Estimate the proportion of HZ

Exploratory objectives:

Risk Factors

1. Estimate the multivariable associations between risk factors and the incidence of HZ amongst those with AID/comorbid conditions.

Healthcare Resource Utilization

1. To describe the HCRU and direct healthcare costs among the general adult (18+) Ontario population with HZ
2. To describe the HCRU and direct healthcare costs among general adult (18+) Ontario population whose HZ developed into PHN
3. To describe the HCRU and direct healthcare costs among individuals with AID or comorbid with HZ
4. To describe the HCRU and direct healthcare costs among individuals with AID or comorbidities whose HZ developed into PHN
5. To compare differences in direct healthcare costs and HCRU among the general adult Ontario population with HZ (Population A-2, see Section 7.2) as well as among individuals with AID or specific comorbidities and HZ (Population B-2) with their respective controls that do not have HZ (Populations A-1 and B-1, respectively), matched using propensity score.

Results: In progress